Showing 6961-6970 of 9228 results for "".
Janssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeVitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.ASDS: Dr. Farah on Hair Loss Treatment Options
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-farah-hair-regrowth-options/29152/Ronda Farah, MD, discusses treatment options for hair loss, including platelet-rich plasma and lasers, at the 2024 American Society for Dermatologic Surgery Annual Meeting.Differentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of itsClinical Data on Switching to Upadacitinib
https://practicaldermatology.com/videos/updates-atopic-dermatitis/clinical-data-on-switching-to-upadacitinib/36534/Clinical investigator Christopher Bunick, MD, PhD, discusses results from the LEVEL UP trial among patients who switched from dupilumab to upadacitinib for atopic dermatitis.Emrosi Launched in the US for Rosacea
https://practicaldermatology.com/videos/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.Achieve Skin Tightening in 1-2-3
https://practicaldermatology.com/conferences/maui-derm-2024/achieve-skin-tightening-in-1-2-3/20239/Mitchel P. Goldman, MD, Founder and Medical Director, Cosmetic Laser Dermatology, and Medical Director, Platinum Dermatology Partners, explains the three basic technologies he swears by to tighten skin.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.DermWireTV: The Year in Review - 2023!
https://practicaldermatology.com/topics/psoriasis/dermwiretv-the-year-in-review-2023/20229/Practical Dermatology® Co-Chief Medical Editor, Joel Schlessinger, MD, shares his thoughts on some of the best products and approvals of 2023 as well as the potential of new JAK inhibitors to treat alopecia areata, vitiligo, psoriasis, and atopic dermatitis. Our new contributor, Andrew Mastro, PA, t